- Sung-wuk Kim, DDS.
Chairman, ImmunoMet Therapeutics
Dr. Sung-wuk Kim has served as Chairman of the Board of Directors and Chief Executive Officer (CEO) since the founding of ImmunoMet Therapeutics, a spinoff of HanAll Biopharma in July 2015. Dr. Kim was previously the CEO of HanAll Biopharma, and during his 12 years in various executive positions, he led a variety of new drug development programs including autoimmune diseases, fibrosis and metabolic diseases. He also pioneered an OXPHOS inhibitor research platform that is designed to target cancer metabolism, which has produced ImmunoMet’s lead drug candidate, IM156. Dr. Kim is an entrepreneur and accomplished inventor, who has made significant contributions to advance drug development, receiving more than 30 patents in a broad range of areas which include formulation, biologics and small molecule drugs.
Dr. Kim has also currently served on the Board of Directors of HanAll Biopharma since 2003 and as Chair of the R&D Committee of Daewoong Pharma Group since 2015. Previously, he served on the Boards of Directors of Humasis Inc, a diagnostics kit development company from 2002 to 2015 and Hangen Biotech, a RSV vaccine development company from 2002 to 2004. Before devoting his career to drug development, Dr. Kim was the founder of an IT entrepreneurial company, Freechal Inc, first XML platform internet community service provider, in 1999 and served on its Board of Directors until 2002.
Dr. Kim earned his Doctorate of Dental Surgery from Yonsei University in Korea.
- Briggs W. Morrison, M.D.
Briggs W. Morrison, M.D. joined ImmunoMet’s Board of Director’s in November 2017. Dr. Morrison currently serves as the CEO and is a member of the board of directors of Syndax Pharmaceuticals, Inc. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm. Prior to joining Syndax and MPM Capital, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, from January 2012 to June 2015, leading the company's global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., from 2007 to January 2012, that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business, and he also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison was Chairman of the Board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, from 2014 to 2015, a member of the executive committee of the Clinical Trials Transformation Initiative (CTTI) sponsored by FDA, and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety) and Oncorus, Inc. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.
- Paul Lammers, M.D., M.Sc.
Paul Lammers, M.D., M.Sc., joined ImmunMet’s Board of Directors in November 2017. Dr. Lammers currently serves as an independent biotech consultant and Scientific Advisor to life sciences companies. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, from Federal and State grants (including CPRIT, the Cancer Prevention and Research Institute from Texas), traditional and strategic venture firms, and by bringing the company public on the Nasdaq Capital Market. In 2009, Dr. Lammers served as President of Repros Therapeutics, The Woodlands, Texas. Prior to Repros Therapeutics, he served six years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of German Pharmaceutical company, Merck KgA. Over his 20 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, and small private and public biotech companies. He began his pharmaceutical career at Organon in the Netherlands, and is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of continuing medical education (CME) programs for medical scientists and healthcare professionals. Dr. Lammers received his Medical Degree and Masters of Science degree from the Catholic University in Nijmegen, The Netherlands.
- Sungsoo Koh, PhD.
Chief Executive Officer, Intercapital Ltd
Sungsoo Koh, PhD, brings 40 years of leadership and expertise in corporate research and finances and M&A. Dr. Koh also currently serves as the CEO of Intercapital Ltd., an investment firm he founded in 1997 and has established his leadership position in corporate growth strategy by closing mergers and acquisitions, financing deals, spin-offs, and listings for a number of companies in pharmaceuticals, biotech, high-tech and telecommunications sectors. Prior to Intercapital, Dr. Koh led the international business operation and equity research division of Hanhwa Securities. He began his career as an investment analyst of the electronics and pharmaceutical industries with Dongsuh Securities Ltd and started to develop his leadership in investment, international business operations and debt financing at the London office of Dongsuh Securities, which he established in 1985.Dr. Koh received his Ph.D. in Finance from City University London and MBA from University of Pittsburgh.
- Bongyong Lee, PhD.
Vice President, Daewoong Pharmaceuticals
Dr. Bongyong Lee has served as a member of our Board of Directors since ImmunoMet’s founding in July 2015. Dr. Lee currently serves as an Executive Vice President of Daewoong Pharmaceuticals, and on the Boards of Directors of HanAll Biopharma, Daewoong ENG and the Korean Pharmaceutical Society. He is also an adjunct professor of Severance Medical School, Yonsei University and the School of Pharmacy, Korea University.
Dr. Lee has been a dedicated scientist and leader in the biopharmaceutical field in Korea, with a distinguished career of more than 30 years of experience in new drug discovery. He has played a pivotal role in the development and commercialization of several drugs: Revoprazan, an acid pump antagonist; Nabota, a botulinum toxin under registration in the USA and EU; Meropenem, a broad-range antibiotic approved in the USA; Aricept patch, a medication launched in the EU for palliative treatment of Alzheimer disease. Dr. Lee is currently focused on the development of first-in-class drug compounds such as Nav1.7 antagonist and proline-tRNA synthase inhibitors. He has also played a key role as the Committee Chair for the "Pharma Korea 2020" Project, an innovative Korean government-sponsored project aimed at developing 20 new drugs under the Ministry of Welfare and Health.
He received the Korean Prime Minister’s Commendation Award in 2015 and the Outstanding Product-Development Award from the Korean FDA in 2007 for his achievements and contribution to drug development programs in Korea.
Dr. Lee earned his Ph.D. in Medicinal Chemistry from the School of Pharmacy, University of Buffalo.
Tae Yong Lee
Chief Executive Officer, InterVest Co., Ltd.
Mr. Tae Yong Lee joined ImmunoMet’s Board of Directors in March 2017. Mr. Lee is the Founder and Co-Chief Executive Officer at InterVest Co., Ltd. He is the Founder of InterVest Bio Investment Fund and Hansing High Tech Investment Fund II and serves as its Chief Executive Officer. Prior to founding the firm, Mr. Lee founded Prime Plus Capital Co., Ltd. Prior to that, he worked as President of Orion Asset Management in New York. He started his career at Tong Yang Securities as an analyst. Mr. Lee holds an M.S. in Economics at Seoul National University.
- Jae Joon Kim
Director, Mirae Asset Venture Investments
Mr. Jae Joon Kim joined ImunoMet’s Board of Directors in March 2016. Mr. Kim is currently a Director of the Venture Investment Division of Korea-based Mirae Asset Venture Investments (Mirae Asset). Since 2009, he has been leading the Venture Investment Division of Mirae Asset and has successfully listed over 15 companies on the NASDAQ, KOSDAQ and KONEX stock market exchanges. He currently manages an equity investment portfolio comprised of more than 30 biopharmaceutical and medical diagnostics companies worldwide.
Mr. Kim has held several positions since joining Mirae Asset in 2006, including the Team Head of the Venture Investment Division and the Team Head of the Corporate Strategic Division.
Prior to joining Mirae Asset, from 2002 to 2006, Mr. Kim was a research associate at Macrogen, a Korea-based biotech company.
Mr. Kim earned a Master’s Degree from the Graduate School of Medicine, Korea University and a Bachelor of Science degree from Korea University.
Copyright © ImmunoMet. All rights reserved.